Next-Level Tissue-Precision Biologics
The Right Drug, for the Right Patient, at the Right LOCATION
Our Vision
A future where immune and inflammatory (I&I) diseases are treated with unmatched precision, safety, and efficacy. We envision a world where organ-specific biologics restore immune balance only where needed—at diseased organs—unlocking long-term remission without the collateral damage of broad, unwanted immunosuppression.
Our Mission
Our mission is to transform the treatment of Immune and Inflammatory (I&I) diseases by pioneering organ-specific, precision-activated biologics that restore immune balance in a targeted and tissue-selective manner — ensuring they remain inactive in circulation and activate only in diseased tissues.
We are dedicated to developing breakthrough, disease-modifying therapies that achieve long-term remission while delivering an unparalleled safety profile — offering superior patient outcomes and unlocking high-value, first-in-class therapeutic opportunities in a rapidly evolving market.
Our Approach
At TregShield Bio, we are redefining the treatment paradigm by engineering next-generation biologics that overcome the practical limitations of powerful but underutilized therapies — as well as future therapies yet to be discovered that could also benefit from this approach. Many biologics today hold immense potential — but are limited by systemic toxicity that prevents optimal dosing and the ability to reach their full therapeutic potential safely.
Our proprietary tissue-activable platform solves this problem by converting these therapies into disease-restricted biologics, unleashing their full potential where it matters most — at the affected organ — while minimizing off-target risks in non-diseased peripheral locations. With a modular, scalable approach, our platform expands both the clinical reach and market value of new and existing biologics across multiple I&I indications, while advancing the frontier of precision medicine.
An Elite Team with Proven Value Creation
United by Innovation, & Built to Execute
TregShield Bio was founded in 2024 to change the way immune and inflammatory (I&I) diseases are treated. At the core of our success is a leadership team and advisory board with decades of combined experience across every critical function of drug development—from discovery, protein engineering, immunology, and computational biology to clinical development, CMC, regulatory strategy, business development, and deal execution.
Our founder and advisors have collectively led or contributed to the development of multiple marketed therapeutics, clinical-stage assets, and multi-million-dollar licensing deals. Their complementary expertise forms the foundation of a biotech company purpose-built for success.
We are driven by scientific excellence, patient impact, and a shared commitment to developing safer, more effective biologics that reimagine the future of autoimmune and inflammatory disease treatment.
Bringing Spatial Precision Activation to Biologics
PRECISION MEDICINE REDEFINED
Next-Level Tissue-Precision Biologics. The Right Drug, for the Right Patient, at the Right LOCATION.
TRANSFORMATIVE PLATFORM TECHNOLOGY
Upgrading Biologics with Spatial Precision Activity. A scalable platform unlocking organ-targeted activity across assets and indications.
TYPE 1 DIABETES FIRST
TRS-001: A Transformative Opportunity in T1D.
First-in-Class, Pancreas-Activable Biologic with Dual Mechanism of Action.
PARTNER WITH US
Join us to advance best-in-class, organ-specific precision biologics for immune and inflammatory diseases. TregShield Bio is actively seeking partners and investors to advance our platform and pipeline.